Zolidronic acid and Charcot's foot
zolidronic acid in the management of Charcot foot: an alternative not to be ignored
Versandkostenfrei!
Versandfertig in 6-10 Tagen
27,99 €
inkl. MwSt.
PAYBACK Punkte
14 °P sammeln!
The objective of this study was to investigate the role of zoledronic acid in the treatment of diabetic Charcot foot. We enrolled 8 type 2 diabetic patients with Charcot neuroarthropathy. All our patients had a complete clinical examination and a podiatric examination. The stage of the neuroathropathy was evaluated. Zolidronic acid was administered to all patients at a dose of 4 mg/100 ml, as an intravenous infusion. We then evaluated the effectiveness of the treatment clinically and radiographically. The mean age of the patients was 61.4 years [55-64]. The mean time to onset of foot pain was ...
The objective of this study was to investigate the role of zoledronic acid in the treatment of diabetic Charcot foot. We enrolled 8 type 2 diabetic patients with Charcot neuroarthropathy. All our patients had a complete clinical examination and a podiatric examination. The stage of the neuroathropathy was evaluated. Zolidronic acid was administered to all patients at a dose of 4 mg/100 ml, as an intravenous infusion. We then evaluated the effectiveness of the treatment clinically and radiographically. The mean age of the patients was 61.4 years [55-64]. The mean time to onset of foot pain was 18.3 years [17-20]. The midfoot involvement was bilateral in 6 patients and unilateral in the other two. The neuroarthropathy was in the state phase of the Eichonholtz classification in 7 patients and in the acute phase in the 8th patient. Standard radiographs of the feet were all abnormal. We noted a disappearance of pain in 6 patients, an improvement of pain in one patient (VAS: decreased by 30%) and a persistence of mechanical pain in 1 patient (VAS 5).
Andere Kunden interessierten sich für
